EGFR and gastric cancer: A phase II/III study comparing varlitinib with 5-FU/leucovorin/oxaliplatin (FOLFOX) versus FOLFOX and placebo as first-line treatment in HER1/HER2 co-expressing advanced GC is currently underway (NCT03130790; Table 3).